Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Best Beauty Stocks to Buy Right Now. BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS) TheFly reported on January 8, 2026, that BofA reduced the price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform rating on the stock. The firm claims that the consensus expectations for sales and EBITDA margins in 2026 are excessively high. It notes that 2026 will be Hims & Hers’ “big investment year” ...

U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ... ...

Company Overview - Teladoc Health has established itself as a pioneer in the adoption and scaling of virtual care over the past 20 years, achieving a leading global position in the industry [2]. Service Segments - The company delivers and orchestrates care across three main segments: virtual care, chronic condition management, and mental health [2]. Future Priorities - Teladoc Health has set priorities for 2025 and is making progress towards these goals, with a focus on key challenges in healthcare [1]. - The company is also outlining areas of focus for 2026, indicating a forward-looking strategy [1].

Teladoc Health (NYSE:TDOC) FY Conference Summary Company Overview - **Company**: Teladoc Health - **Industry**: Virtual healthcare services - **Revenue**: Generated $2.5 billion in revenues on a trailing 12-month basis as of Q3 2025, with over $270 million in Adjusted EBITDA [3][2] Core Business Segments - **Integrated Care**: Largest segment, providing virtual care, chronic condition management, and mental health services. Over 100 million people in the U.S. have access to their products and services, with over 12,000 clients [3][2] - **BetterHelp**: The largest virtual therapy business globally, serving over 5 million people in 100 countries. The segment has faced challenges since 2023, particularly in the U.S. market [9][10] Key Strategic Priorities 1. **Enhancing U.S. Integrated Care**: Focus on clinical impact and innovation [14] 2. **Leveraging Mental Health Position**: Strengthening the role in virtual mental health services [14] 3. **Growing International Value**: Expanding international operations and tailoring services to local markets [15] 4. **Operational Excellence**: Improving business performance and efficiency [15] Financial Performance and Trends - **Revenue Model Shift**: Over 50% of revenues from virtual care are now visit-based arrangements, indicating a shift from subscription models [50] - **User Engagement**: BetterHelp has a conversion rate of less than 20% from potential users due to cost barriers; moving to insurance coverage is expected to improve this [11][12] Innovations and Technology - **Prism Care Delivery Platform**: Enhancements made to improve integrated care delivery and patient engagement [5][54] - **Pulse Data Platform**: Utilizes AI to analyze data for better patient outcomes and operational efficiency [6][55] - **New Offerings for 2026**: Introduction of new products in virtual care, chronic condition management, and mental health [16] International Expansion - **Localized Models**: Operating in seven countries with local language support and therapists [16] - **Hybrid Care Models**: Combining virtual services with physical care settings, particularly in rural areas [25] Challenges and Market Dynamics - **Healthcare Affordability**: Ongoing challenges include medical cost inflation and unmet mental health needs [13] - **Consumer Market Pressures**: BetterHelp's direct-to-consumer model has faced challenges, prompting a shift to insurance-based coverage [10][12] Future Outlook - **2026 Focus**: Emphasis on execution and bringing new products to market, with a strong financial position to support growth initiatives [29][28] - **AI Integration**: Continued focus on leveraging AI across various aspects of healthcare delivery [42][44] Conclusion - **Strategic Positioning**: Teladoc Health aims to address significant healthcare challenges through innovative solutions and operational improvements, with a focus on enhancing user experience and expanding its market presence [29][30]

Core Insights - VSee Health, Inc. has launched an AI-enhanced Rural Health Transformation Solution aimed at improving access to specialty care, clinical outcomes, and financial performance for rural hospitals without increasing fixed staffing costs [1] Group 1: Product Launch - The new platform is modular, allowing for customization to meet the specific needs of rural healthcare providers [1] - The launch is strategically timed with the Centers for Medicare & Medicaid Services (CMS) announcement of $10 billion in funding for rural health initiatives over the next five years [1] Group 2: Financial Implications - The Rural Health Transformation Program (RHTP) will provide $10 billion annually to support rural hospitals, which may enhance the financial sustainability of these institutions [1] - The solution aims to strengthen the financial performance of rural hospitals, potentially leading to improved operational efficiency [1]

Investment Opportunities in Space Sector - The space sector is expected to continue its momentum into 2026, with the RCSpace and Defense Innovation ETF rising 50% in 2025 [3][5] - SpaceX is rumored to have an IPO in 2026, potentially valued at $1.5 trillion, which could positively impact other speculative stocks in the sector [4][5] - Rocket Lab (RKLB) is highlighted as a leading company in the space sector, with a preference for it over SpaceX [5] - Redwire (RDW) is noted for its role as a component manufacturer for space and drones, with potential for profitability in 2026 following a significant acquisition in 2025 [5][8] - The space sector is characterized by high risk and speculation, with many companies currently unprofitable [6][9] Investment Opportunities in Healthcare Sector - TransMedics Group is a medical device company that has developed an organ care system (OCS) for organ transplantation, which is FDA-approved and enhances organ viability during transport [15][16] - The company has transitioned to a fully integrated logistics and service provider, operating its own fleet of aircraft for organ transport [15] - TransMedics holds over 50% market share in the U.S. for portable organ systems and is initiating major clinical trials that could drive future growth [16][18] - Hims & Hers is a healthcare company disrupting traditional models, focusing on telehealth and compounding facilities, with a significant short interest of over 30% [20][24] - The company is involved in the GLP-1 market, which has generated both interest and skepticism among investors, but it is noted that GLP-1s represent only 20% of their business [25][28]

Core Insights - The article discusses the rising interest in GLP-1 weight loss medications, particularly the search for the "best GLP-1 weight loss shot," reflecting both curiosity and confusion among consumers [6][7][8]. Group 1: Market Trends and Consumer Behavior - The search volume for "best GLP-1 weight loss shot" has increased significantly, indicating a growing consumer interest in weight loss options [6]. - Between 2020 and 2024, GLP-1 receptor agonist prescriptions saw a dramatic increase, continuing into 2026 as new medication formats were introduced [7]. - Factors driving this sustained interest include positive clinical trial results, celebrity endorsements, and the introduction of oral GLP-1 formulations, such as the FDA-approved oral semaglutide [8][9]. Group 2: Clinical Evaluation of GLP-1 Medications - Clinicians evaluate GLP-1 treatment eligibility based on individual health profiles rather than determining which medication is "best" [11][16]. - FDA-approved GLP-1 medications are generally indicated for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities [12]. - Health history, contraindications, and individual treatment goals significantly influence the decision-making process for GLP-1 medication [13][14]. Group 3: Medication Formats and Differences - The GLP-1 medication landscape includes injectable, oral, and compounded formats, each with distinct characteristics [17]. - Injectable GLP-1 medications are the most established, with clinical trials showing significant average weight loss outcomes [18]. - Oral GLP-1 formulations, such as oral semaglutide, require specific adherence patterns and may appeal to patients who prefer non-injectable options [19]. - Compounded GLP-1 medications are prepared by compounding pharmacies and are not FDA-approved, which patients should understand when considering their options [20]. Group 4: Side Effects and Monitoring - Common side effects of GLP-1 medications include gastrointestinal issues, which are most prevalent during initial dosing [24]. - Serious risks, such as pancreatitis and potential thyroid tumor risk, are included in prescribing information and should be discussed with healthcare providers [25]. - Ongoing monitoring is essential for patients on GLP-1 medications to assess response and adjust treatment as necessary [26]. Group 5: Telehealth Access and Process - Direct Meds is a telehealth platform that connects patients with independent licensed healthcare providers for GLP-1 medication evaluations [30][44]. - The process involves a comprehensive health intake followed by a virtual consultation to determine the appropriateness of GLP-1 treatment [31]. - Telehealth platforms like Direct Meds help address access barriers while ensuring medical oversight through licensed providers [34].

NEWARK, DE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription treatments that require evaluation by a licensed clinician. Compounded medications are not FDA-approved as finished products. Always consult a qualified healthcare professional before starting any prescription weight loss treatment. Some readers access services through affiliate links in this article, and a commission may be earn ...

Core Insights - Consumer interest in peptide therapy and NAD+-focused therapies is increasing as research highlights the significance of NAD+ in cellular processes [3][56] - Understanding delivery methods such as injectable, oral, and intravenous is crucial for informed decision-making among consumers [3][15] Delivery Method Characteristics - Consumers are comparing NAD+-related therapies based on administration settings, supervision requirements, and bioavailability [15] - Oral supplementation of NAD+ precursors like NMN and NR requires gastrointestinal absorption, which can vary among individuals [16][17] - Intravenous (IV) NAD+ therapy delivers the compound directly into the bloodstream, bypassing digestive processes, but typically requires in-person appointments [18][19] - Subcutaneous injections offer a middle-ground approach, allowing home administration under clinical supervision, facilitated by telehealth platforms [21] Telehealth Platforms and Prescription Therapy Access - The expansion of telehealth services has created new pathways for accessing prescription therapies that require clinical oversight [23] - Telehealth platforms operate through a three-entity model involving technology platforms, licensed healthcare providers, and compounding pharmacies [24][25] - RenuviaRX is an example of a telehealth platform that facilitates access to NAD+ injections through its infrastructure [27][28] Pricing and Availability Information - RenuviaRX lists NAD+ injection programs starting at approximately $179 per month, with additional therapies available at varying prices [31][32] - Services are currently available in 47 states, with some states having regulatory restrictions on telehealth services [32] Understanding Therapy Categories - NAD+ and its precursors relate to cellular energy pathways and repair mechanisms, often discussed alongside peptide therapies [34] - Other compounds available through RenuviaRX include Glutathione, L-Carnitine, and Vitamin B12, each with distinct characteristics and benefits [38] Consumer Considerations for Telehealth Therapy Access - Individuals interested in telehealth should assess their comfort with remote evaluations and self-administration protocols [39][40] - Those with complex medical histories or specific health conditions should prioritize in-person evaluations before considering telehealth options [41]

Investors with a lot of money to spend have taken a bearish stance on Hims & Hers Health (NYSE:HIMS).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HIMS, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner ...